SCHEMBL17350112

SCHEMBL17350112

COc1cc(Oc2ccc(NC(=O)[C@@H](C)NC(=O)O)cc2)ccc1C

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MTNR1B P49286 3/20 0.52
MAPK1 P28482 1/20 0.46
MAPT P10636 2/20 0.45
SMN1; SMN2 Q16637 3/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
GAA P10253 2/20 0.43
MTNR1A P48039 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
PGR P06401 1/20 0.43
MCL1 Q07820 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
HTT P42858 2/20 0.42
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1979299 0.90 MTNR1B (0.52) MTNR1BMAPK1MAPTSMN1; SMN2MEN1
SCHEMBL17350063 0.88 SMN1; SMN2 (0.57) MTNR1BMAPK1MAPTSMN1; SMN2MEN1
SCHEMBL12593803 0.87 MTNR1B (0.46) MTNR1BMAPK1MAPTMEN1KMT2A
SCHEMBL17350062 0.86 KMT2A (0.45) MAPK1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL1978552 0.85 XIAP (0.55) MTNR1BMAPK1MAPTSMN1; SMN2MEN1
SCHEMBL17350083 0.84 MTNR1B (0.74) MTNR1BMAPK1SMN1; SMN2MTNR1AALDH1A1
SCHEMBL21980958 0.83 MTNR1B (0.52) MTNR1BMAPK1MAPTSMN1; SMN2MEN1
SCHEMBL1978976 0.83 MTNR1B (0.52) MTNR1BMAPK1MAPTSMN1; SMN2MEN1
SCHEMBL13720959 0.80 MTNR1B (0.46) MTNR1BMAPTSMN1; SMN2MEN1KMT2A
SCHEMBL17549697 0.80 AAK1 (0.48) MTNR1BKMT2AMTNR1AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200163964-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2020-05-28 US disclosed
US-10632118-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2020-04-28 US disclosed
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-11-29 US disclosed
US-10058551-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2018-08-28 US disclosed
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-01-25 US disclosed
US-9849131-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2017-12-26 US disclosed
US-20170065585-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2017-03-09 US disclosed
EP-2509961-B1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LTD (GB) 2016-03-09 EP disclosed
US-20160058737-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2016-03-03 US disclosed
US-9216967-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2015-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 MTNR1B 1903/4885MAPK1 808/4885MAPT 3762/4885
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 MTNR1B 1903/4885MAPK1 808/4885MAPT 3762/4885
US-10632118-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 MTNR1B 1903/4885MAPK1 808/4885MAPT 3762/4885
US-20170065585-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 MTNR1B 1903/4885MAPK1 808/4885MAPT 3762/4885
US-20160058737-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 MTNR1B 1903/4885MAPK1 808/4885MAPT 3762/4885
US-10058551-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 MTNR1B 1903/4885MAPK1 808/4885MAPT 3762/4885
US-20200163964-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 MTNR1B 1903/4885MAPK1 808/4885MAPT 3762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.